Interview, Fireside Chat, Conference Presentation
a16z Podcast | The Science and Business of Innovative Medicines
- Novartis plans to exit subscale operations and discontinue projects that do not redefine the standard of care, prioritizing capital allocation toward specific high-impact areas rather than spreading resources thinly.
- The company anticipates a 10-year timeline to rebuild R&D expertise, such as in infectious diseases, should the decision to abandon an area be reversed.
- Drug development success rates are expected to remain approximately 5% industry-wide (with Novartis averaging 8% to 10%), meaning roughly one in 20 candidates will enter human testing.
- Clinical trial costs are projected to increase linearly per patient due to growing complexity and regulatory requirements, unless technology deployment reduces expenses by an estimated 20%.
- Technology adoption is viewed as essential to manage costs, with specific expectations that AI will improve efficiency in trial enrollment, quality control, and pathology analysis.
- A shift from incremental improvements to transformative clinical benefits is required, driven by a need to justify premium pricing through measurable value propositions.
- The industry is expected to evolve from a "bespoke" model to a modular, iterative approach similar to medical devices, with regenerative medicine focusing on specific tissues like cartilage and tendons for healthy aging.
- Xenotransplantation is predicted to become feasible within the next 10 to 20 years, enabling the creation of transplantable organs from animals.
- Manufacturing for cell and gene therapies is currently in a "learning to crawl" phase, necessitating a cultural shift from artisanal methods to factory-like processes for reproducibility.
- The company intends to own nascent cell and gene therapy platforms internally while eventually outsourcing mature supply chain elements.
- Data science and AI are identified as core trajectories, though effective machine learning on unstructured data requires years of data cleaning before yielding insights.
- Reimbursement strategies will shift to occur early in the development phase, working backwards to ensure a viable value proposition.
- Real-world evidence and continuous wearables will be used to supplement clinical data between visits but are not expected to replace randomized, blinded trials.
- Future talent strategies involve partnering with universities and startups, establishing "Biome" centers in hubs like San Francisco and London to source data scientists.
- Organizational culture must adapt to "inspired, curious, and unbossed" dynamics, embracing rapid failure and iteration in unpredictable new spaces.
- Behavioral interventions are expected to play an increasing role in treating complex diseases like Alzheimer's and type 2 diabetes, alongside the development of digital therapeutics for conditions such as obesity.
- Leadership skills will increasingly focus on multidisciplinary exposure and people management rather than purely technical expertise.
- The company faces significant challenges in overcoming the "not invented here" syndrome, requiring open debate and potentially housing new platforms as independent units.
- The ultimate goal for clinical trials involves integrated health records and blockchain architectures to eliminate separate databases, though this remains an ideal state.
- The vast scale of the company, operating in 150 countries with 120,000 employees, presents a major hurdle for driving necessary transformations.